← All Psyence Biomedical LTD filings

Psyence Biomedical LTD 20-F annual reports

The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.

NASDAQ
PBM
Psyence Biomedical LTD
20-F/A: Psyence Biomedical Amends Annual Report to Include Internal Control Statement
Psyence Biomedical Ltd. filed an amendment to its annual report to include the previously omitted management's report on internal control over financial reporting, confirming its effectiveness.
NASDAQ
PBM
Psyence Biomedical LTD
20-F: Psyence Biomedical Reports Significant Financial Turnaround and Advances Psilocybin Clinical Trials for Palliative Care
Psyence Biomedical Ltd. reported a net profit of $1 million for the fiscal year ended March 31, 2025, a substantial improvement from the prior year's $50.96 million loss, driven by fair value gains on debt conversion and warrant remeasurement, while advancing its Phase IIb psilocybin-assisted psychotherapy study in Australia.
NASDAQ
PBM
Psyence Biomedical LTD
20-F: Psyence Biomedical Ltd. Files 20-F Report for Fiscal Year Ended March 31, 2024
Psyence Biomedical Ltd. releases its 20-F report, detailing financial performance and operational activities for the fiscal year ending March 31, 2024, highlighting a significant net loss due to listing expenses and ongoing clinical trial developments.
NASDAQ
PBM
Psyence Biomedical LTD
20-F: Psyence Biomedical Completes Business Combination with Newcourt Acquisition Corp, Secures Nasdaq Listing
Psyence Biomedical finalized its merger with Newcourt Acquisition Corp on January 25, 2024, resulting in a Nasdaq listing under the ticker PBM.